We believe that our present findings of chemopreventive and therapeutic efficacy of an epigenetic dietary agent pterostilbene as a novel MTA1-targeted strategy, may have potential clinical applications in prostate cancer management. This evidence concerns the gene MTA1 and Familial prostate cancer.